Chdi Foundation, Inc.

Summit Corporation Plc

Summit Therapeutics Plc

The University of Southampton

Oxagen Limited

Peter David Johnson

Celia Dominguez

Michael Edward Prime

Christopher John Brown

John Wityak

Jonathan Bard

Daniel Clark-Frew

Colin Richard Dorgan

Graham Michael Wynne

Sarah Hayes

Leticia M Toledo-Sherman

William Mitchell

Samuel Coe

Richard Storer

Olivier De Moor

Francis Xavier Wilson

Alex Kiselyov

Matthew Robert Mills

Stephen Martin Courtney

Paula C De Aguiar Pena

Thomas Martin Krülle

Stephen Paul Wren

Paul Richard Giles

Sébastien René Gabriel Galan

Thomas Martin Krulle

Richard Waldron Marston

Alan Geoffrey Roach

Richard Vickers

Paul James Davis

Duane Higgins

Samantha Brown

Longbin Liu

Martin John Glennie

Richard Edward Armer

Ingrid Teige

Matthew Randolf Lee

Mark Steven Cragg

Naomi Went

Ali Roghanian

Stephen Beers

Sean Lim

Elise Luciennen Paulette Gadouleau

Richard Joseph Pye

Gary Nugent

Paul Damien Price

Richard John Vickers

Renate Maria Van Well

Lauren Jayne Sudlow

Ignacio Muñoz-Sanjuán

Daryl Simon Walter

Inaki Morao

Ignacio Muñoz-Sanjuan

Malcolm George Taylor

Filippo Rota

Kanika Khurana

Adrian Kotey

Catherine Jane Greenaway

Elise Lucienne Paulette Gadouleau

Derek Alexander Weddell

Jonathon Mark Tinsley

Ian James Wigginton

Bjoern Frendeus

Renate Van Well

William Leonard Mitchell

Collin Richard Dorgan

Ignacio Munoz

Björn Frendeus

Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.

Probes for imaging huntingtin protein

Provided herein are certain compounds and imaging agents useful for detecting a condition or disorder associated with protein aggregation, compositions thereof, and methods of their use.

Compounds and probes for imaging huntingtin protein

Provided herein are certain compounds and imaging agents useful for detecting a disease or condition associated with protein aggregation, compositions thereof, and methods of their use.

Heterocyclic compounds and imaging agents for imaging huntingtin protein

Probes for imaging Huntingtin protein

The invention provides a method of treating a patient having target cells that express Fc&#x3b3;RIIb, the method comprising administering (i) an antibody molecule that specifically binds a surface antigen of the target cell, which antibody molecule has an Fc domain capable of binding Fc&#x3b3;RIIb; in combination with (ii) an agent that prevents or reduces binding between the Fc domain of the antibody molecule and Fc&#x3b3;RIIb; characterized in that the patient is selected on the basis that their target cells express an elevated level of Fc&#x3b3;RIIb.

Combined use of Fc&#x3b3;RIIb (CD32B) and CD20 specific antibodies

Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use. 

Provided are imaging agents comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and methods of their use. 

The invention provides a method of treating a patient having target cells that express FcyRIIb, the method comprising administering (i) an antibody molecule that specifically binds a surface antigen of the target cell, which antibody molecule has an Fc domain capable of binding FcyRIIb; in combination with (ii) an agent that prevents or reduces binding between the Fc domain of the antibody molecule and FcyRIIb; characterized in that the patient is selected on the basis that their target cells express an elevated level of FcyRIIb.

Combined use of Fc gamma RIIb (CD32B) and CD20-specific antibodies

Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof

Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use 

Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

Growing community of inventors

Abingdon, United Kingdom

Peter David Johnson